Cases & Deals

  • Home
  • Practices
  • Royalty Pharma acquires Oxlumo™ royalty interest from Dicerna

Share

Royalty Pharma acquires Oxlumo™ royalty interest from Dicerna

April 2021

Client(s) RP Management LLC

Jones Day advised Royalty Pharma in the acquisition of an interest in Dicerna’s royalty in Dicerna’s OXLUMO™ (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.